KR100890473B1 - 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진 - Google Patents

혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진 Download PDF

Info

Publication number
KR100890473B1
KR100890473B1 KR1020027003972A KR20027003972A KR100890473B1 KR 100890473 B1 KR100890473 B1 KR 100890473B1 KR 1020027003972 A KR1020027003972 A KR 1020027003972A KR 20027003972 A KR20027003972 A KR 20027003972A KR 100890473 B1 KR100890473 B1 KR 100890473B1
Authority
KR
South Korea
Prior art keywords
methyl
pyridazin
alkyl
amino
oxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020027003972A
Other languages
English (en)
Korean (ko)
Other versions
KR20020038775A (ko
Inventor
자크 피. 듀마스
테디 카이트 조
해롤드 씨. 이. 클루엔더
웬디 리
다나팔란 나가라쓰남
로버트 엔. 시블리
닝 수
스티븐 제임스 보이어
줄리 에이. 딕슨
Original Assignee
바이엘 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 코포레이션 filed Critical 바이엘 코포레이션
Publication of KR20020038775A publication Critical patent/KR20020038775A/ko
Application granted granted Critical
Publication of KR100890473B1 publication Critical patent/KR100890473B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
KR1020027003972A 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진 Expired - Lifetime KR100890473B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28
US09/407,600 1999-09-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
KR1020087021380A Division KR100895572B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR1020087021379A Division KR100895571B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진

Publications (2)

Publication Number Publication Date
KR20020038775A KR20020038775A (ko) 2002-05-23
KR100890473B1 true KR100890473B1 (ko) 2009-03-26

Family

ID=23612752

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020027003972A Expired - Lifetime KR100890473B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR1020087021379A Expired - Lifetime KR100895571B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR1020087021380A Expired - Lifetime KR100895572B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020087021379A Expired - Lifetime KR100895571B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR1020087021380A Expired - Lifetime KR100895572B1 (ko) 1999-09-28 2000-09-26 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진

Country Status (35)

Country Link
EP (1) EP1228063B1 (enExample)
JP (1) JP4919567B2 (enExample)
KR (3) KR100890473B1 (enExample)
CN (3) CN100422172C (enExample)
AR (3) AR025752A1 (enExample)
AT (1) ATE422494T1 (enExample)
AU (1) AU782820B2 (enExample)
BG (1) BG65860B1 (enExample)
BR (1) BRPI0014382B8 (enExample)
CA (1) CA2385817C (enExample)
CO (1) CO5200835A1 (enExample)
CZ (1) CZ304767B6 (enExample)
DE (1) DE60041548D1 (enExample)
DO (1) DOP2000000070A (enExample)
EE (1) EE05258B1 (enExample)
ES (1) ES2320525T3 (enExample)
GT (1) GT200000158A (enExample)
HR (1) HRP20020308A2 (enExample)
HU (1) HU230223B1 (enExample)
IL (3) IL148880A0 (enExample)
MA (1) MA25563A1 (enExample)
MX (1) MXPA02003156A (enExample)
MY (3) MY143377A (enExample)
NO (1) NO20021520L (enExample)
NZ (1) NZ518589A (enExample)
PA (1) PA8503201A1 (enExample)
PE (1) PE20010607A1 (enExample)
PL (1) PL205957B1 (enExample)
RS (1) RS50369B (enExample)
RU (1) RU2260008C2 (enExample)
SK (1) SK287417B6 (enExample)
TW (1) TW593315B (enExample)
UA (1) UA75053C2 (enExample)
WO (1) WO2001023375A2 (enExample)
ZA (1) ZA200202760B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416525A1 (en) * 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
US20050019424A1 (en) * 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
EP1603566B1 (en) * 2003-03-11 2009-01-21 Novartis AG Use of isoquinoline derivatives for treating cancer and map kinase related diseases
EP1616576A4 (en) * 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp SPECIFIC NAD (P) H OXIDASE HEMMER
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-ｃ]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
EP1797877A4 (en) 2004-09-13 2010-12-15 Eisai Co Ltd JOINT USE OF A SULFONAMIDE-BASED COMPOUND AND AN ANGIOGENESIS INHIBITOR
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007118602A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
CN101481380B (zh) 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular
JP7624404B2 (ja) * 2019-04-22 2025-01-30 ミラティ セラピューティクス，インク． Ｐｒｃ２阻害剤としてのナフチリジン誘導体
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035958A1 (en) * 1997-02-13 1998-08-20 Novartis Ag Phthalazines with angiogenesis inhibiting activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
CA2173493C (en) * 1994-08-09 2008-03-25 Nobuhisa Watanabe Fused pyridazine compounds
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
EP1107964B8 (en) * 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
JP4673977B2 (ja) * 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
PT1254138E (pt) * 2000-02-09 2005-09-30 Novartis Ag Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035958A1 (en) * 1997-02-13 1998-08-20 Novartis Ag Phthalazines with angiogenesis inhibiting activity

Also Published As

Publication number Publication date
BR0014382B1 (pt) 2014-04-01
CN1769282A (zh) 2006-05-10
EP1228063A2 (en) 2002-08-07
SK5912002A3 (en) 2003-01-09
HU230223B1 (en) 2015-10-28
BG65860B1 (bg) 2010-03-31
IL193367A (en) 2011-03-31
MY143377A (en) 2011-05-13
CN100422172C (zh) 2008-10-01
KR20020038775A (ko) 2002-05-23
WO2001023375A2 (en) 2001-04-05
HRP20020308B1 (enExample) 2013-01-31
CO5200835A1 (es) 2002-09-27
KR100895572B1 (ko) 2009-04-29
JP2003526632A (ja) 2003-09-09
RU2260008C2 (ru) 2005-09-10
MY143580A (en) 2011-05-31
AR025752A1 (es) 2002-12-11
TW593315B (en) 2004-06-21
HUP0202704A2 (hu) 2002-12-28
EE200200161A (et) 2003-08-15
DOP2000000070A (es) 2002-02-28
IL193368A (en) 2011-05-31
PA8503201A1 (es) 2002-08-26
ZA200202760B (en) 2003-10-29
ES2320525T3 (es) 2009-05-25
HK1091818A1 (zh) 2007-01-26
CN100422173C (zh) 2008-10-01
AR082231A2 (es) 2012-11-21
NZ518589A (en) 2005-03-24
PL205957B1 (pl) 2010-06-30
AR082232A2 (es) 2012-11-21
PE20010607A1 (es) 2001-07-12
AU1569601A (en) 2001-04-30
NO20021520L (no) 2002-05-23
UA75053C2 (en) 2006-03-15
SK287417B6 (sk) 2010-09-07
BR0014382A (pt) 2003-06-24
CN1420879A (zh) 2003-05-28
BRPI0014382B8 (pt) 2021-05-25
PL366342A1 (en) 2005-01-24
AU782820B2 (en) 2005-09-01
EP1228063B1 (en) 2009-02-11
CN100374435C (zh) 2008-03-12
IL193367A0 (en) 2009-02-11
YU22902A (sh) 2004-12-31
CZ20021444A3 (cs) 2002-08-14
MXPA02003156A (es) 2002-09-30
RS50369B (sr) 2009-11-10
HRP20020308A2 (en) 2004-06-30
GT200000158A (es) 2002-03-16
WO2001023375A3 (en) 2002-05-02
HUP0202704A3 (en) 2003-12-29
EE05258B1 (et) 2010-02-15
CZ304767B6 (cs) 2014-10-08
CA2385817A1 (en) 2001-04-05
MY135058A (en) 2008-01-31
KR20080086547A (ko) 2008-09-25
KR20080091505A (ko) 2008-10-13
DE60041548D1 (de) 2009-03-26
ATE422494T1 (de) 2009-02-15
JP4919567B2 (ja) 2012-04-18
CN1769283A (zh) 2006-05-10
IL148880A0 (en) 2002-09-12
CA2385817C (en) 2010-05-04
IL193368A0 (en) 2009-02-11
NO20021520D0 (no) 2002-03-26
MA25563A1 (fr) 2002-10-01
HK1091819A1 (zh) 2007-01-26
KR100895571B1 (ko) 2009-04-29
BG106637A (bg) 2003-02-28

Similar Documents

Publication Publication Date Title
KR100895571B1 (ko) 혈관신생 억제 활성을 갖는 치환 피리딘 및 피리다진
KR20020019969A (ko) 혈관신생 억제 활성을 갖는 치환 피리다진 및 융합 피리다진
US6689883B1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US20110263597A1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US8304406B2 (en) Compounds for treating pulmonary hypertension
CA3093323C (en) Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof
HK1091818B (en) Substitued pyridines and pyridazines with angiogenesis inhibiting activity
HK1091819B (en) Substitued pyridines and pyridazines with angiogenesis inhibiting activity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20020327

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050926

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060728

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080901

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20081224

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20090318

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20090318

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20120308

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20120308

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20130308

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20130308

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20140310

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20140310

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20150306

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20150306

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20160308

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20160308

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20170314

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20170314

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20180307

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20180307

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20190311

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20190311

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20200309

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20200309

Start annual number: 12

End annual number: 12

EXPY Expiration of term
PC1801 Expiration of term